<p><strong>Pineal Capital Management</strong> 呼吁 <strong>Teladoc Health Inc.</strong> (NYSE: TDOC) 的董事会采取紧急措施以释放股东价值，警告称公司低迷的估值使其面临潜在的机会主义收购风险。</p>
<p>这家投资顾问通过 Pineal Capital Fund 1 持有 Teladoc 的股份，表示已与管理层接触数月，但对董事会在关键战略问题上的缓慢行动感到担忧。</p>
<p>Pineal 认为，尽管 Teladoc 在 虚拟医疗领域 处于领先地位，并且全球会员超过 1 亿，但其当前市场价格显著低估了其长期增长前景。</p>
<p>Benzinga 联系了 Teladoc，询问对 Pineal Capital 信的评论，但在发布时未收到回复。</p>
<h2>对资本配置和治理的担忧</h2>
<p>该公司强调了一系列影响投资者信心的失误，包括过去的收购和资本配置决策。</p>
<p>它特别指出 2020 年收购 Livongo 的交易，称其被高估且时机不当，质疑在当时股权估值强劲的情况下，部分用债务融资该交易的决定。</p>
<p>更近期的交易——包括 Catapult、UpLift 和 Telecare Australia 也受到审查，Pineal 指出对其财务贡献缺乏清晰度，并强调与某些交易相关的商誉减值。</p>
<p>投资者进一步批评缺乏股票回购，认为 Teladoc 在股票显著被低估和资产负债表低杠杆的情况下未采取行动。</p>
<h2>Teladoc 股票表现和沟通缺口</h2>
<p>Teladoc 的股票自 COVID 前高点以来已下跌超过 90%，尽管公司加强了其竞争地位。</p>
<p>Pineal 表示，缺乏清晰的多年度战略，包括有限的投资者沟通和没有最近的投资者日，增加了市场的不确定性。</p>
<p>该公司还指出，基于股票的补偿导致持续的股权稀释，指出自 2020 年以来，流通股几乎翻倍，而没有进行相应的回购。</p>
<h2>提议的价值释放策略</h2>
<p>Pineal 概述了一个三部分计划以改善业绩，包括成本削减、超过 2 亿美元的股票回购计划和全面的战略审查。</p>
<p>该审查可能包括将 Teladoc 的综合护理和 BetterHelp 部门分开，Pineal 认为这将消除 “综合折扣” 并释放价值。</p>
<h2>增长顺风和隐藏的资产价值</h2>
<p>尽管存在批评，Pineal 强调了强劲的基本面，包括有利的政策变化、24/7 虚拟护理平台的推出以及 BetterHelp 基于保险的模式的增长。</p>
<p>该公司还将 Teladoc 的心理健康部门视为 “隐藏的皇冠明珠”，预计 2025 年相关收入超过 11 亿美元，并具有显著的长期增长潜力。</p>
<p>它补充说，最近在类似交易中的估值倍数，如 Talkspace，进一步突显了 Teladoc 当前估值与其内在价值之间的脱节。</p>
<h2>TDOC 报告强于预期的季度业绩</h2>
<p>在 2 月，Teladoc Health 报告每股亏损 14 美分，优于 市场共识的 18 美分亏损。</p>
<p>此外，销售额增加至 6.4227 亿美元，超过预期的 6.3524 亿美元，主要受其他收入来源增长 24% 的推动，尽管接入费用收入下降了 4%。</p>
<p>Teladoc Health 预计 2026 年第一季度 亏损将在 35-45 美分之间，而市场共识为 25 美分，销售额为 5.98 亿至 6.2 亿美元，而 共识为 6.3375 亿美元。</p>
<p>这家远程医疗公司预计 2026 财年亏损在 70 美分至 1.10 美元之间，销售额在 24.7 亿至 25.9 亿美元之间，而市场共识分别为 76 美分和 25.55 亿美元。</p>
<p><strong>TDOC 股票价格活动：</strong> 在发布时，Teladoc Health 的股票下跌 0.64%，报 5.52 美元， 根据 Benzinga Pro 数据。</p>
<p><em>图片来源于 Teladoc</em></p>

FDHT

TDOC

HEAL

远程医疗和数字健康 ETF - GlobalX

<p>Pineal Capital Management 正在敦促 Teladoc Health Inc. 通过回购、成本削减和战略审查来提升股东价值，理由是对其低估值和潜在收购风险的担忧。该公司批评了过去的收购和缺乏回购，指出自 COVID-19 前的高点以来，Teladoc 的股票已下跌超过 90%。Pineal 提出了一个三部分的战略以改善业绩，强调了 Teladoc 在心理健康领域的强大基本面和增长潜力。尽管最近的季度业绩超出预期，但在发布时，Teladoc 的股价下跌了 0.64%，报 $5.52</p>

<p><strong>Pineal Capital Management</strong> has called on the board of <strong>Teladoc Health Inc.</strong> (NYSE: TDOC) to take urgent steps to unlock shareholder value, warning that the company's depressed valuation leaves it exposed to a potential opportunistic takeover.</p>
<div class="lb-trans"><p><strong>Pineal Capital Management</strong> 呼吁 <strong>Teladoc Health Inc.</strong> (NYSE: TDOC) 的董事会采取紧急措施以释放股东价值，警告称公司低迷的估值使其面临潜在的机会主义收购风险。</p>
</div><p>The investment advisor, which holds a stake in Teladoc through Pineal Capital Fund 1, said it has engaged with management for months but remains concerned about the board's slow pace of action on critical strategic issues.</p>
<div class="lb-trans"><p>这家投资顾问通过 Pineal Capital Fund 1 持有 Teladoc 的股份，表示已与管理层接触数月，但对董事会在关键战略问题上的缓慢行动感到担忧。</p>
</div><p>Pineal argues that Teladoc's current market price significantly undervalues its long-term growth prospects, despite its leadership position in virtual healthcare and a member base exceeding 100 million users globally.</p>
<div class="lb-trans"><p>Pineal 认为，尽管 Teladoc 在 虚拟医疗领域 处于领先地位，并且全球会员超过 1 亿，但其当前市场价格显著低估了其长期增长前景。</p>
</div><p>Benzinga reached out to Teladoc for comment on the Pineal Capital letter but did not receive a response at the time of publication.</p>
<div class="lb-trans"><p>Benzinga 联系了 Teladoc，询问对 Pineal Capital 信的评论，但在发布时未收到回复。</p>
</div><h2>Concerns Over Capital Allocation And Governance</h2>
<div class="lb-trans"><h2>对资本配置和治理的担忧</h2>
</div><p>The firm highlighted a series of missteps that have weighed on investor confidence, including past acquisitions and capital allocation decisions.</p>
<div class="lb-trans"><p>该公司强调了一系列影响投资者信心的失误，包括过去的收购和资本配置决策。</p>
</div><p>It specifically pointed to the 2020 Livongo acquisition, which it described as overvalued and poorly timed, questioning the decision to partially fund the deal with debt despite a strong equity valuation at the time.</p>
<div class="lb-trans"><p>它特别指出 2020 年收购 Livongo 的交易，称其被高估且时机不当，质疑在当时股权估值强劲的情况下，部分用债务融资该交易的决定。</p>
</div><p>More recent deals—including Catapult, UpLift, and Telecare Australia—were also scrutinized, with Pineal noting a lack of clarity on their financial contribution and highlighting goodwill impairments tied to some transactions.</p>
<div class="lb-trans"><p>更近期的交易——包括 Catapult、UpLift 和 Telecare Australia 也受到审查，Pineal 指出对其财务贡献缺乏清晰度，并强调与某些交易相关的商誉减值。</p>
</div><p>The investor further criticized the absence of share buybacks, arguing that Teladoc has failed to act despite a significantly undervalued stock and an under-levered balance sheet.</p>
<div class="lb-trans"><p>投资者进一步批评缺乏股票回购，认为 Teladoc 在股票显著被低估和资产负债表低杠杆的情况下未采取行动。</p>
</div><h2>Teladoc Stock Performance And Communication Gaps</h2>
<div class="lb-trans"><h2>Teladoc 股票表现和沟通缺口</h2>
</div><p>Teladoc shares have declined more than 90% from pre-COVID highs, even as the company strengthened its competitive positioning.</p>
<div class="lb-trans"><p>Teladoc 的股票自 COVID 前高点以来已下跌超过 90%，尽管公司加强了其竞争地位。</p>
</div><p>Pineal said the lack of a clearly articulated multi-year strategy, including limited investor communication and no recent Investor Day, has added to market uncertainty.</p>
<div class="lb-trans"><p>Pineal 表示，缺乏清晰的多年度战略，包括有限的投资者沟通和没有最近的投资者日，增加了市场的不确定性。</p>
</div><p>The firm also flagged ongoing equity dilution from stock-based compensation, noting that shares outstanding have nearly doubled since 2020 without offsetting buybacks.</p>
<div class="lb-trans"><p>该公司还指出，基于股票的补偿导致持续的股权稀释，指出自 2020 年以来，流通股几乎翻倍，而没有进行相应的回购。</p>
</div><h2>Proposed Value-Unlock Strategy</h2>
<div class="lb-trans"><h2>提议的价值释放策略</h2>
</div><p>Pineal outlined a three-part plan to improve performance, including cost reductions, a $200 million-plus share repurchase program, and a full strategic review.</p>
<div class="lb-trans"><p>Pineal 概述了一个三部分计划以改善业绩，包括成本削减、超过 2 亿美元的股票回购计划和全面的战略审查。</p>
</div><p>The review could include separating Teladoc's Integrated Care and BetterHelp segments, which Pineal believes would eliminate a &#34;conglomerate discount&#34; and unlock value.</p>
<div class="lb-trans"><p>该审查可能包括将 Teladoc 的综合护理和 BetterHelp 部门分开，Pineal 认为这将消除 “综合折扣” 并释放价值。</p>
</div><h2>Growth Tailwinds And Hidden Asset Value</h2>
<div class="lb-trans"><h2>增长顺风和隐藏的资产价值</h2>
</div><p>Despite its criticisms, Pineal emphasized strong underlying fundamentals, including favorable policy changes, the rollout of a 24/7 virtual care platform, and growth in BetterHelp's insurance-based model.</p>
<div class="lb-trans"><p>尽管存在批评，Pineal 强调了强劲的基本面，包括有利的政策变化、24/7 虚拟护理平台的推出以及 BetterHelp 基于保险的模式的增长。</p>
</div><p>The firm also identified Teladoc's mental health segment as a &#34;hidden crown jewel,&#34; citing over $1.1 billion in related revenue in 2025 and significant long-term growth potential.</p>
<div class="lb-trans"><p>该公司还将 Teladoc 的心理健康部门视为 “隐藏的皇冠明珠”，预计 2025 年相关收入超过 11 亿美元，并具有显著的长期增长潜力。</p>
</div><p>It added that recent valuation multiples in comparable transactions, such as Talkspace, further highlight the disconnect between Teladoc's current valuation and its intrinsic worth.</p>
<div class="lb-trans"><p>它补充说，最近在类似交易中的估值倍数，如 Talkspace，进一步突显了 Teladoc 当前估值与其内在价值之间的脱节。</p>
</div><h2>TDOC Reported Stronger-Than-Expected Quarterly Results</h2>
<div class="lb-trans"><h2>TDOC 报告强于预期的季度业绩</h2>
</div><p>In February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents.</p>
<div class="lb-trans"><p>在 2 月，Teladoc Health 报告每股亏损 14 美分，优于 市场共识的 18 美分亏损。</p>
</div><p>Additionally, sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%.</p>
<div class="lb-trans"><p>此外，销售额增加至 6.4227 亿美元，超过预期的 6.3524 亿美元，主要受其他收入来源增长 24% 的推动，尽管接入费用收入下降了 4%。</p>
</div><p>Teladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million.</p>
<div class="lb-trans"><p>Teladoc Health 预计 2026 年第一季度 亏损将在 35-45 美分之间，而市场共识为 25 美分，销售额为 5.98 亿至 6.2 亿美元，而 共识为 6.3375 亿美元。</p>
</div><p>The telehealth company sees a fiscal 2026 loss of 70 cents to $1.10, with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion, respectively.</p>
<div class="lb-trans"><p>这家远程医疗公司预计 2026 财年亏损在 70 美分至 1.10 美元之间，销售额在 24.7 亿至 25.9 亿美元之间，而市场共识分别为 76 美分和 25.55 亿美元。</p>
</div><p><strong>TDOC Stock Price Activity:</strong> Teladoc Health shares were down 0.64% at $5.52 at the time of publication on Wednesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>TDOC 股票价格活动：</strong> 在发布时，Teladoc Health 的股票下跌 0.64%，报 5.52 美元， 根据 Benzinga Pro 数据。</p>
</div><p><em>Image via Teladoc</em></p>
<div class="lb-trans"><p><em>图片来源于 Teladoc</em></p>
</div>

Teladoc 因资本配置和股票表现不佳而面临压力